Company intelligence / Profile preview
RNACure
Shanghai, Shanghai, China
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
The company, through its program RQ3013 (in partnership with Walvax), demonstrated promising Phase 3b data as a heterologous mRNA COVID-19 vaccine booster, showing superior immunogenicity and solid relative vaccine efficacy (62.2–69.0%), coupled with good safety, especially in older adults.
- Therapeutic areas
- OncologyInfectious DiseasesRare Diseases
- Modalities
- mRNA-based drugsRNA therapy
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →03
Partnerships
Walvax Biotechnology Co., Ltd.Local universities and research institutions (unnamed)
Beyond the preview
Go deeper on RNACure.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RNACure.